Metabolic Disorders

insitro collaborates with Lilly on metabolic disease treatments

Machine learning-enabled drug discovery and development company insitro has executed three agreements with Lilly to advance new treatments for metabolic diseases.

Diamyd Medical secures FDA fast track status for type 1 diabetes treatment

Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.

Aardvark Therapeutics secures $85m in Series C funding round

Aardvark Therapeutics has secured $85m in an oversubscribed Series C financing round, with Decheng Capital spearheading the investment, to complete studies of ARD-101.

Rhythm and Genpharm to commercialise IMCIVREE in GCC countries

Rhythm Pharmaceuticals and Genpharm Services FZ have announced a partnership to commercialise IMCIVREE (setmelanotide) for patients in Gulf Cooperation Council (GCC) countries.

Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS

Rhythm Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for IMCIVREE (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).